Evaluation of long-term safety of the anti-IgE antibody, omalizumab, in children with allergic asthma

Annals of Allergy, Asthma and Immunology

Volumn 91, Issue 2, 2003, Pages 182-188

  Berger, William E ^a,c   Gupta, Niroo ^b   McAlary, Margaret ^b   Fowler Taylor, Angel ^b  

^a Mission Viejo Medical Center   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; BECLOMETASONE DIPROPIONATE; DRUG ANTIBODY; IMMUNOGLOBULIN E ANTIBODY; OMALIZUMAB; PLACEBO;

ALLERGIC ASTHMA; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; EVALUATION; FEMALE; HEADACHE; HUMAN; IMMUNE COMPLEX DISEASE; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SERUM SICKNESS; UPPER RESPIRATORY TRACT INFECTION; URTICARIA;

EID: 0043240429     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)62175-8     Document Type: Article

References (24)

1. Newacheck PW, Halfon N. Prevalence, impact, and trends in childhood disability due to asthma. Arch Pediatr Adolesc Med. 2000;154:287-293.
2. Burrows B, Martinez FD, Halonen M, Barbee RA, Cline MG. Association of asthma with serum IgE levels and skin-test reactivity to allergens. N Engl J Med. 1989;320:271-277.
3. Holgate ST. The inflammatory basis of asthma and its implications for drug treatment. Clin Exp Allergy. 1996;26(Suppl):1-4.
4. Martinez FD, Wright AL, Taussig LM, Holberg CJ, Halonen M, Morgan WJ. Asthma and wheezing in the first six years of life. The Group Health Medical Associates. N Engl J Med. 1995;332:133-138.
5. National Asthma Education and Prevention Program. Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma. Bethesda, MD: National Institutes of Health/ National Heart, Lung, and Blood Institute; 1997. Publication 97-4051.
6. Presta L, Shields R, O'Connell L, et al. The binding site on human immunoglobulin E for its high affinity receptor. J Biol Chem. 1994;269:26368-26373.
7. Presta LG, Lahr SJ, Shields RL, et al. Humanization of an antibody directed against IgE. J Immunol. 1993;151:2623-2632.
8. Liu J, Lester P, Builder S, Shire SJ. Characterization of complex formation by humanized anti-IgE monoclonal antibody and monoclonal human IgE. Biochemistry. 1995;34:10474-10482.
9. Shields RL, Werther WR, Zioncheck K, et al. Anti-IgE monoclonal antibodies that inhibit allergen-specific histamine release. Int Arch Allergy Immunol. 1995;107:412-413.
10. Bisberg D, Froehlich J, Schoenhoff M, et al. Multiple administration of the anti-IgE recombinant humanized monoclonal antibody E25 (rhuMAb-E25) reduces free IgE levels in a dose-dependent manner in adolescent children with moderate to severe asthma. J Clin Pharmacol. 1996;36:859.
11. Boulet LP, Chapman KR, Cote J, et al. Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response. Am J Respir Crit Care Med. 1997;155:1835-1840.
12. Heusser C, Jardieu P. Therapeutic potential of anti-IgE antibodies. Curr Opin Immunol. 1997;9:805-813.
13. Chang TW. The pharmacological basis of anti-IgE therapy. Nat Biotechnol. 2000;18:157-162.
14. Fahy JV, Fleming HE, Wong HH, et al. The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med. 1997;155:1828-1834.
15. MacGlashan DW Jr, Bochner BS, Adelman DC, et al. Down-regulation of FcεRI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol. 1997;158:1438-1445.
16. Metzger WJ, Fick RB, the E25 Asthma Study Group. Corticosteroid (CS) withdrawal in a study of a recombinant humanized monoclonal antibody to IgE (rhuMAb-E25). J Allergy Clin Immunol. 1998;101:S231.
17. Milgrom H, Fick RB Jr, Su JQ, et al. Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group. N Engl J Med. 1999;341:1966-1973.
18. Milgrom H, Berger W, Nayak A, et al. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics. 2001;108:E36. Available at: www.pediatrics.org/ egi/content/full/108/2/e36.
19. Casale TB, Bernstein IL, Busse WW, et al. Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis. J Allergy Clin Immunol. 1997;100:110-121.
20. Merrett J, Merrett TG. Screening for IgE-mediated allergy. J Clin Immunoassay. 1993;16:164-172.
21. Bazartal M, Hamburger RN. Standardization and stability of immunoglobulin E (IgE). J Allergy Clin Immunol. 1972;49:189-191.
22. Fox JA, Reitz B, Hagler K, et al. The pharmacokinetics and clearance mechanisms of anti-IgE:IgE monoclonal and polyclonal complexes. Pharm Res. 1997;14:217C.
23. Saini SS, MacGlashan DW Jr, Sterbinsky SA, et al. Down-regulation of human basophil IgE and FcεRI a surface densities and mediator release by anti-IgE-infusions is reversible in vitro and in vivo. J Immunol. 1999;162:5624-5630.
24. Barnes PJ, Woolcock AJ. Difficult asthma. Eur Respir J. 1998;12:1209-1218.